In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...Read More
Ongoing treatment(s)-Chemotherapy Posts on Medivizor
Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.
In a nutshell This study investigated the effectiveness and safety outcomes of nimotuzumab (Theraloc) combined with chemoradiotherapy (CRT) for the treatment of patients with locally advanced squamous non-small cell lung cancer (SqNSCLC). The data showed that nimotuzumab plus CRT had similar survival outcomes compared to CRT alone, but with a lower...Read More
Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia
In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL). This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...Read More
In a nutshell This study evaluated the impact of different times after chemotherapy until breast cancer surgery on complications after surgery and survival outcomes. The data showed the optimal time to surgery (TTS) was between 21 and 28 days after chemotherapy in these patients. Some background Breast cancer (BC) is one of...Read More
Can reducing chemotherapy duration from 6 to 3 months reduce side effects in patients with colorectal cancer and still be effective?
In a nutshell This study investigated if reducing therapy duration could reduce side effects in patients but still be effective in patients with stage II colorectal cancer (CRC). This study showed that in certain patients a 3-month treatment duration can be considered. Some background Patients with colorectal cancer (CRC) can be treated...Read More
In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...Read More
In a nutshell This study examined whether a healthy diet can improve the quality of life of women with breast cancer undergoing chemotherapy. The authors found that women who followed healthy dietary advice had an improvement in the quality of their life during chemotherapy, reducing nausea, vomiting, and increasing appetite. Some background...Read More
How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?
In a nutshell This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome. Some background Rectal cancer is commonly treated with surgery to remove the tumor. LARC is...Read More
Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?
In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP. Some...Read More
The effect of chemotherapy dose intensity on outcomes for patients with aggressive adult T-cell leukemia/lymphoma
In a nutshell This study aimed to investigate the effect of chemotherapy dose intensity on outcomes for patients with adult T-cell leukemia/lymphoma. This study concluded that higher chemotherapy dose intensity improves outcomes for these patients. Some background Adult T-cell leukemia/lymphoma (ATL) is an aggressive blood cancer. It can...Read More
In a nutshell This study investigated the effectiveness and safety of pembrolizumab (Keytruda) plus chemotherapy in patients with inoperable or metastatic triple-negative breast cancer. The data showed that the combination is effective in improving progression-free survival in these patients. Some background Triple-negative breast cancer (TNBC)...Read More
Cetuximab combined with irinotecan improves the outcomes of patients with advanced colorectal cancer
In a nutshell This study investigated the effectiveness of irinotecan (Camptosar) with and without cetuximab (Erbitux) in the treatment of metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that combined treatment improves the outcomes of these patients. Some background Colorectal cancer (CRC) is one of...Read More